$2995 | Single User
$4495 | Multi User
$8995 | Site License
$14995 | Global License

Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010-2018 [Report Updated: 01-03-2018]

Published by Current Partnering: 01 Mar 2018 | 195858 | In Stock

Introduction

The Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010- 2018 report is your one-stop source for providing real-deal information on hundreds of transactions, including the technology licensed, royalty rates, license fees, upfront and milestone payments.


This report provides details of the latest partnering deals which disclose a royalty rate, announced in the pharmaceutical, biotechnology and diagnostic sectors. The report provides details of partnering deals disclosing royalty rates from 2010 to 2018.


The report provides an overview of how and why companies enter partnering deals where a royalty is payable upon commercialization of the compound or technology.


Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.


This report contains a comprehensive listing of all partnering deals announced since 2010 where a quantitative royalty rate has been disclosed, as recorded in the Current Agreements deals and alliances database. Each deal record and royalty disclosure is available in further detail via a link to online copy of the deal including actual contract document, where available, as submitted to the Securities Exchange Commission by companies and their partners.


The initial chapters of this report provide an orientation of royalty rate trends in pharma and biotech since 2010. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in royalty rates in the pharma and biotech sectors since 2010, including a summary of the recent literature on the subject.


Chapter 3 provides an average benchmark royalty rates. The chapter includes numerous tables and figures summarizing the benchmark royalty rates by stage of development, therapy area and technology area.


Chapter 4 provides a more detailed insight into the structure of a royalty rate clause and how it fits with the other financial terms of the partnering deal. The chapter includes numerous case studies for actual deals where royalty rates have been disclosed.


Chapter 5 provides an insight into companies active in disclosing royalty rates as well as those deals attracting the highest royalty rates, and why.


Chapter 6 provides comprehensive and detailed access to deals which disclose a royalty rate since 2010 where a contract document is available. Contract documents provide an in-depth insight into the actual deal terms agreed between the parties with respect to the royalty rate.


In addition the report includes a comprehensive appendix listing of all deals where a royalty rate has been disclosed announced since 2010. Each listing is organized as an appendix by company A-Z, stage of development at signing, therapeutic area, and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.


The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.


The report also includes numerous table and figures that illustrate the trends in royalty rates in pharma and biotech deal making since 2010.


In conclusion, this report provides everything a prospective dealmaker needs to know about royalty rates in the pharma and biotech sector.


Key benefits


Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010- 2018 provides the reader with the following key benefits:


In-depth understanding of royalty rate partnering deal trends since 2010

Analysis of the structure of royalty clauses with numerous real life case studies

Comprehensive listing of all partnering deals since 2010 where a royalty rate is disclosed, together with deal terms, value and press release

Comprehensive access to actual partnering deal contracts entered into by the world’s life science companies where a royalty rate is disclosed

Insight into the royalty terms included in a licensing agreement, together with real world clause examples

Understand the key deal terms companies have agreed in previous deals

Undertake due diligence to assess suitability of your proposed deal terms for partner companies


Report scope


Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010- 2018 is intended to provide the reader with an in-depth understanding of the royalty rate trends and structure of deals entered into by leading life science companies worldwide.


Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010- 2018 includes:


Trends in royalty rates in the biopharma industry since 2010

Analysis of royalty rate clause structure

Case studies of real-life licensing deals which disclose royalty rates

Comprehensive listing of licensing deals which disclose royalty rates since 2010

Access to licensing contract documents which disclose royalty rates

The leading licensing deals by royalty rate value since 2010

Most active royalty rate disclosures since 2010


In Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010- 2018 available deals and contracts are listed by:


Company A-Z

Headline value

Therapeutic area

Technology type


Each deal title links via Weblink to an online version of the actual deal record and where available, contract document, providing easy access to each contract document on demand.


The Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010-2018 report provides comprehensive access to available contract documents for licensing deals. Analyzing actual contract agreements allows assessment of the following:


What are the precise royalty rates granted?

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What is the payment structure for the deal?

How are sales and payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

Table of Contents
for Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010-2018 [Report Updated: 01-03-2018]

  • Executive Summary

    Chapter 1 – Introduction

    1.1. What are royalties?

    1.2. History of royalty rates

    1.3. Royalties in pharma and biotech

    1.4. Royalties versus revenue share

    1.5. Overview of the report

    Chapter 2 – An overview of pharma and biotech royalty rates

    2.1. Trends in royalty rates 2010-2015

    2.2. Royalty rate disclosure in pharma and biotech

    2.3. How do revenue shares figure?

    2.4. A review of recent literature

    2.5. Royalty rates in the future

    Chapter 3 – Average royalty rates for pharma and biotech partnering

    3.1. Royalty rates in early stage deals

    3.2. Royalty rates by stage of development

    3.3. Royalty rates by therapy area

    Chapter 4 – The royalty clause in pharma and biotech deals

    4.1. Partnering agreement structure

    4.2. Structure of a typical royalty clause

    4.3. Example royalty clauses

    4.3.1. Case study 1: Merck Serono-Opexa Therapeutics

    4.3.2. Case study 2: Aradigm - Grifols

    4.3.3. Case study 3: Forect Laboratories - Trevena

    4.3.4. Case study 4: Sage Therapeutics – University of California

    Chapter 5 – Companies actively disclosing royalty rates

    5.1. Fifty most active companies in disclosing royalty rates

    5.2. Top partnering deals by royalty rate

    5.3. The role of bigpharma and bigbiotech in royalty rate disclosure

    5.2. Top partnering deals by royalty rate

    Chapter 6 – Royalty rate contract directory

    Explore royalty rates within the deal contract document to gain greater insight

    Appendices

    Appendix 1 – Royalty rates in deals – by company A-Z

    Appendix 2 – Royalty rates in deals - by therapy area

    Appendix 3 – Royalty rates in deals - by stage of development at signing

    Appendix 4 – Royalty rates in deals - by technology type

    Appendix 5 – Royalty rate references

    Appendix 6 – Resources

    Appendix 7 – Deal type definitions

    Appendix 8 – Example royalty rate deal contract document

    About Wildwood Ventures

    Current Partnering

    Current Agreements

    Recent report titles from Current Partnering

    TABLE OF FIGURES

    Figure 1: Trends in pharma and biotech royalty rates, 2010-2018

    Figure 2: Royalty rates in early stage at deal signing – 2010-2018

    Figure 3: Royalty rates by phase of development at deal signing – 2010-2018

    Figure 4: Royalty rates by therapy area – 2010-2018

    Figure 5: Components of the partnering deal structure

    Figure 6: Components of the partnering royalty clause

    Figure 7: Most active companies disclosing royalty rate 2010-2018

    Figure 8: Top deals by royalty rate 2010-2018

    Figure 9: Deals disclosing revenue share 2010-2018

    Figure 10: Online partnering resources

    Figure 11: Deal type definitions

    Figure 12: Licensing agreement for rhAAT – rEVO Biologics, LFB Biotechnologies

Additional Details

Publisher

Current Partnering

Publisher Information

Reference

195858 | CP2013

Number of Pages

350

Report Format

PDF

Current Partnering Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Global Royalty Financing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2018
The Global Royalty Financing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010...
01 Mar 2018 by Current Partnering USD $1,995 More Info
Semiconductor IP Market by Design IP (processor IP, interface IP, memory IP), Source (royalty and licensing), vertical (consumer electronics, telecom, industrial, automotive, commercial), and Geography - Global Forecast to 2023
“The semiconductor IP market is expected to grow at a CAGR of 4.87% between 2017 and 2022”The semico...
11 Oct 2017 by MarketsandMarkets USD $5,650 More Info
Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010-2017
The Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010- 2017 report is your one-stop s...
01 Sep 2017 by Current Partnering USD $2,995 More Info
Global Royalty Financing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017
The Global Royalty Financing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010...
01 Sep 2017 by Current Partnering USD $1,995 More Info
Global Royalty Financing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017
The Global Royalty Financing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010...
01 Feb 2017 by Current Partnering USD $1,995 More Info
Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010-2017
The Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010- 2017 report is your one-stop s...
01 Feb 2017 by Current Partnering USD $2,995 More Info
Royalty Pharma - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryRoyalty Pharma is a life sciences financing company that offers diversified and balanced port...
30 Nov 2016 by Global Data USD $250 More Info
Royalty Pharma - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryRoyalty Pharma is a life sciences financing company that provides diversified and balanced po...
12 May 2016 by Global Data USD $250 More Info
Royalty Pharma – Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
SummaryMarketLine's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments r...
15 Apr 2016 by Marketline USD $350 More Info
Royalty Pharma - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryRoyalty Pharma is a life sciences financing company that provides diversified and balanced po...
15 Mar 2016 by Global Data USD $250 More Info

This report is published by Current Partnering

Download Free Report Summary PDF

Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010-2018 [Report Updated: 01-03-2018] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • Allied Market Research
  • CBR Pharma
  • Current Partnering
  • Firstword
  • Global Data
  • Global Markets Direct
  • ICD Research
  • Infinti Research Technavio
  • Marketline
  • Markets and Markets
  • Micro Markets Monitor
  • MP Advisors
  • Venture Planning Group
  • GMR Data